JP2007511611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511611A5 JP2007511611A5 JP2006541555A JP2006541555A JP2007511611A5 JP 2007511611 A5 JP2007511611 A5 JP 2007511611A5 JP 2006541555 A JP2006541555 A JP 2006541555A JP 2006541555 A JP2006541555 A JP 2006541555A JP 2007511611 A5 JP2007511611 A5 JP 2007511611A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cholinesterase inhibitors
- group
- mixtures
- serotonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 81
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 41
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 22
- 239000000935 antidepressant agent Substances 0.000 claims 21
- 229940005513 antidepressants Drugs 0.000 claims 21
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 11
- 229960001623 desvenlafaxine Drugs 0.000 claims 11
- 229960003980 galantamine Drugs 0.000 claims 11
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 11
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 9
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 9
- 229960004136 rivastigmine Drugs 0.000 claims 9
- 229960004688 venlafaxine Drugs 0.000 claims 9
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 9
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 8
- 230000001430 anti-depressive effect Effects 0.000 claims 8
- 229960001653 citalopram Drugs 0.000 claims 8
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 7
- 229960003530 donepezil Drugs 0.000 claims 7
- 229960002073 sertraline Drugs 0.000 claims 6
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 5
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 5
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 5
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 5
- -1 demepotassium Chemical compound 0.000 claims 5
- 229960002866 duloxetine Drugs 0.000 claims 5
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 5
- 229960002296 paroxetine Drugs 0.000 claims 5
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 5
- 230000004580 weight loss Effects 0.000 claims 5
- UBIQMAFTTDZGEX-UHFFFAOYSA-N 1-[7-[(dimethylamino)methyl]-4-methoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]cyclohexan-1-ol Chemical compound C12=CC(OC)=CC=C2CC1(CN(C)C)C1(O)CCCCC1 UBIQMAFTTDZGEX-UHFFFAOYSA-N 0.000 claims 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 229960001058 bupropion Drugs 0.000 claims 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 4
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 4
- 229960004341 escitalopram Drugs 0.000 claims 4
- 229960004038 fluvoxamine Drugs 0.000 claims 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 4
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000952 serotonin receptor agonist Substances 0.000 claims 3
- 230000000697 serotonin reuptake Effects 0.000 claims 3
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 claims 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims 2
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 claims 2
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 claims 2
- RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 claims 2
- ZOBDWFRKFSPCRB-UNMCSNQZSA-N [(4as,9as)-2,4a,9-trimethyl-4,9a-dihydro-3h-oxazino[6,5-b]indol-6-yl] n-(2-ethylphenyl)carbamate Chemical compound CCC1=CC=CC=C1NC(=O)OC1=CC=C(N(C)[C@@H]2[C@@]3(C)CCN(C)O2)C3=C1 ZOBDWFRKFSPCRB-UNMCSNQZSA-N 0.000 claims 2
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 claims 2
- 229960000451 ambenonium Drugs 0.000 claims 2
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 claims 2
- 229960000959 amineptine Drugs 0.000 claims 2
- ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 claims 2
- 229960003748 edrophonium Drugs 0.000 claims 2
- 229950010753 eptastigmine Drugs 0.000 claims 2
- 229960005051 fluostigmine Drugs 0.000 claims 2
- 229950000264 ganstigmine Drugs 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 229960002362 neostigmine Drugs 0.000 claims 2
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 claims 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- 229960001697 physostigmine Drugs 0.000 claims 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 2
- 229960002290 pyridostigmine Drugs 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 229960001685 tacrine Drugs 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical group C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 229960002430 atomoxetine Drugs 0.000 claims 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 1
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical group O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 claims 1
- 229950000017 befloxatone Drugs 0.000 claims 1
- 229960002837 benzphetamine Drugs 0.000 claims 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- 229960003572 cyclobenzaprine Drugs 0.000 claims 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960000632 dexamfetamine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002672 isocarboxazid Drugs 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 229950001413 metamfepramone Drugs 0.000 claims 1
- KBHMHROOFHVLBA-UHFFFAOYSA-N metamfepramone Chemical compound CN(C)C(C)C(=O)C1=CC=CC=C1 KBHMHROOFHVLBA-UHFFFAOYSA-N 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001952 metrifonate Drugs 0.000 claims 1
- 229960000600 milnacipran Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004644 moclobemide Drugs 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960001779 pargyline Drugs 0.000 claims 1
- 229960000436 phendimetrazine Drugs 0.000 claims 1
- 229960000964 phenelzine Drugs 0.000 claims 1
- 229960003209 phenmetrazine Drugs 0.000 claims 1
- 229960003562 phentermine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229960002601 protriptyline Drugs 0.000 claims 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960003741 tranylcypromine Drugs 0.000 claims 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims 1
- 229960002431 trimipramine Drugs 0.000 claims 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 1
- 239000003174 triple reuptake inhibitor Substances 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 239000013585 weight reducing agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52361003P | 2003-11-19 | 2003-11-19 | |
| US10/993,496 US20050143350A1 (en) | 2003-11-19 | 2004-11-18 | Combination drug therapy to treat obesity |
| PCT/US2004/038981 WO2005051297A2 (en) | 2003-11-19 | 2004-11-19 | Combination drug therapy to treat obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511611A JP2007511611A (ja) | 2007-05-10 |
| JP2007511611A5 true JP2007511611A5 (https=) | 2007-12-27 |
Family
ID=34636478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541555A Withdrawn JP2007511611A (ja) | 2003-11-19 | 2004-11-19 | 肥満を処置するための薬物併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050143350A1 (https=) |
| EP (1) | EP1684712A4 (https=) |
| JP (1) | JP2007511611A (https=) |
| KR (1) | KR20060109493A (https=) |
| AU (1) | AU2004293008A1 (https=) |
| BR (1) | BRPI0416700A (https=) |
| CA (1) | CA2545655A1 (https=) |
| IL (1) | IL175615A0 (https=) |
| RU (2) | RU2363458C2 (https=) |
| SG (1) | SG148169A1 (https=) |
| WO (1) | WO2005051297A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US20070166363A1 (en) * | 2004-02-19 | 2007-07-19 | Lane Roger M | Use of cholinesterase inhibitors for treating vascular depression |
| WO2005115471A2 (en) * | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| US7968538B2 (en) * | 2005-01-25 | 2011-06-28 | Galenea Corp. | Substituted arylamine compounds and methods of treatment |
| WO2006138475A2 (en) * | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| WO2007012154A1 (en) * | 2005-07-27 | 2007-02-01 | Carlos Henrique Horta Lima | Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties. |
| ES2362926T3 (es) * | 2005-09-22 | 2011-07-15 | EISAI R&D MANAGEMENT CO., LTD. | Nueva combinación de fármacos como un antidepresivo. |
| EP1938811A4 (en) * | 2005-09-22 | 2008-12-17 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS |
| US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| WO2008019431A1 (en) * | 2006-08-14 | 2008-02-21 | Brc Operations Pty Limited | Method and compositions for simultaneously regulating memory and mood |
| RU2452474C2 (ru) * | 2006-12-01 | 2012-06-10 | Нитто Денко Корпорейшн | Стабилизированная адгезивная композиция, содержащая донепезил |
| US20100062045A1 (en) * | 2006-12-01 | 2010-03-11 | Nitto Denko Corporation | Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed |
| AU2008302190A1 (en) * | 2007-09-18 | 2009-03-26 | Stephen Wills | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors |
| CA2723949A1 (en) * | 2008-05-19 | 2009-11-26 | Nestec S.A. | Methods for reducing lipid absorption by an animal |
| RU2481826C2 (ru) * | 2008-05-30 | 2013-05-20 | Нитто Денко Корпорейшн | Содержащий донепезил адгезивный препарат и упаковка для него |
| CN102046171B (zh) * | 2008-05-30 | 2013-06-19 | 日东电工株式会社 | 经皮吸收制剂 |
| US8633252B2 (en) * | 2009-01-26 | 2014-01-21 | Taipei Medical University | Use of pterosin compounds for treating diabetes and obesity |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| SMT201700578T1 (it) | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US8440655B2 (en) | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| WO2012048243A2 (en) * | 2010-10-08 | 2012-04-12 | University Of Utah Research Foundation | Depression disorder therapeutics with creatine analogs |
| WO2012050348A2 (ko) * | 2010-10-13 | 2012-04-19 | 한국과학기술원 | 역률보상형 엘이디 조명장치 |
| US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
| US11998516B2 (en) * | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| US20150157672A1 (en) * | 2013-12-09 | 2015-06-11 | Phytology Labs, Inc. | Kits and methods for sustained weight loss |
| WO2015120299A1 (en) | 2014-02-07 | 2015-08-13 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
| MY186047A (en) | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| US20190175610A1 (en) * | 2017-12-07 | 2019-06-13 | Glykon Technologies Group, Llc | Formulation of galantamine and carnitine and method of fatty acid mobilization |
| MX2020006140A (es) | 2017-12-11 | 2020-08-13 | Tonix Pharma Holdings Ltd | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. |
| KR20250099037A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 에아스텍 | 리코라민을 유효성분으로 함유하는 혈전 관련 질환 또는 대사성 질환의 예방, 개선 또는 치료용 조성물 |
| WO2025245102A2 (en) * | 2024-05-21 | 2025-11-27 | S1 Biopharma, Inc. | Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
| US3673177A (en) * | 1970-05-04 | 1972-06-27 | American Cyanamid Co | Substituted 4-(anilinomethylene)-3-galanthamaninones |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4248857A (en) * | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4252786A (en) * | 1979-11-16 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Controlled release tablet |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4895845A (en) * | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| US6204284B1 (en) * | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| EP0567090B1 (en) * | 1992-04-24 | 2000-07-26 | Takeda Chemical Industries, Ltd. | Benzoxazepine derivatives as cholinesterase inhibitors |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| TW248556B (https=) * | 1993-01-18 | 1995-06-01 | Takeda Pharm Industry Co | |
| DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| DE69429895T2 (de) * | 1993-06-28 | 2002-08-29 | American Home Products Corp., Madison | Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten |
| US6316439B1 (en) * | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US5620973A (en) * | 1993-11-30 | 1997-04-15 | Takeda Chemical Industries, Ltd. | Tetracyclic condensed heterocyclic compounds and their use |
| US5428159A (en) * | 1994-04-08 | 1995-06-27 | Ciba-Geigy Corporation | Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine |
| RU2161159C2 (ru) * | 1994-11-02 | 2000-12-27 | Жансен Фармасетика Н.В. | Замещенные тетрациклические производные оксазепина и тиазепина, способ их получения, композиция, обладающая антипсихотической активностью, и способ ее получения |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| IL131713A (en) * | 1997-03-11 | 2004-08-31 | Arakis Ltd | Dosage forms comprising separate portions of r- and s-enantiomers |
| CA2282390A1 (en) * | 1997-04-17 | 1998-10-22 | Yukio Fujisawa | Thermogenic composition and benzazepine thermogenics |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| US6313919B1 (en) * | 1997-07-02 | 2001-11-06 | Canon Kabushiki Kaisha | Printing control apparatus and method |
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| ATE294577T1 (de) * | 1999-02-24 | 2005-05-15 | Univ Cincinnati | Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6688640B1 (en) * | 1999-08-17 | 2004-02-10 | Lear Corporation | Tethered air bag cover |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| US20010043957A1 (en) * | 2000-02-25 | 2001-11-22 | Morris Mann | Lypolytic composition |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| AR032455A1 (es) * | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
| DOP2001000154A (es) * | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
| US6533540B1 (en) * | 2000-06-09 | 2003-03-18 | Sta-Rite Industries, Inc. | Double-seal/oil-reservoir system for a motor/pump assembly |
| CA2354877C (en) * | 2000-08-18 | 2006-05-02 | H. Lundbeck A/S | Method for the preparation of citalopram |
| ES2194597B2 (es) * | 2002-01-25 | 2004-08-01 | Esteve Quimica, S.A. | Procedimiento para la obtencion de citalopram. |
-
2004
- 2004-11-18 US US10/993,496 patent/US20050143350A1/en not_active Abandoned
- 2004-11-19 SG SG200808316-4A patent/SG148169A1/en unknown
- 2004-11-19 EP EP04811669A patent/EP1684712A4/en not_active Withdrawn
- 2004-11-19 AU AU2004293008A patent/AU2004293008A1/en not_active Abandoned
- 2004-11-19 CA CA002545655A patent/CA2545655A1/en not_active Abandoned
- 2004-11-19 RU RU2006121453/14A patent/RU2363458C2/ru not_active IP Right Cessation
- 2004-11-19 JP JP2006541555A patent/JP2007511611A/ja not_active Withdrawn
- 2004-11-19 KR KR1020067012113A patent/KR20060109493A/ko not_active Withdrawn
- 2004-11-19 WO PCT/US2004/038981 patent/WO2005051297A2/en not_active Ceased
- 2004-11-19 BR BRPI0416700-7A patent/BRPI0416700A/pt not_active IP Right Cessation
-
2006
- 2006-05-14 IL IL175615A patent/IL175615A0/en unknown
-
2009
- 2009-04-07 RU RU2009113038/15A patent/RU2009113038A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511611A5 (https=) | ||
| RU2006121453A (ru) | Комбинированная лекарственная терапия для лечения ожирения | |
| US20110195952A1 (en) | Treating psychological conditions using muscarinic receptor m1 antagonists | |
| JP2007513052A5 (https=) | ||
| JP2007505156A5 (https=) | ||
| JP5371762B2 (ja) | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 | |
| Jarrott et al. | The current status of monoamine oxidase and its inhibitors | |
| AU5533200A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| RU2455981C2 (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
| US6403650B1 (en) | Treatment of pulmonary hypertension | |
| JP2022521208A5 (https=) | ||
| JP2024538015A5 (https=) | ||
| Krähenbühl | Adverse Effects and Drug-Drug Interactions | |
| WO2000056316A1 (en) | Treatment of gallstones | |
| CA2367045A1 (en) | Treatment of certain cancers associated with weight gain |